Prime Medicine is a biotechnology company committed to delivering a class of differentiated one-time curative genetic therapies, Prime Editors, to address a spectrum of diseases by deploying Prime Editing technology. Co.'s in-licensed Prime Editing technology has the ability to repair mutations. Prime Editors have two main components that act together to edit deoxyribonucleic acid (DNA): a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The PRME average annual return since 2022 is shown above.
The Average Annual Return on the PRME average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRME average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRME average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|